Nuvectis Pharma (NVCT) EPS (Weighted Average and Diluted) (2021 - 2026)
Nuvectis Pharma has reported EPS (Weighted Average and Diluted) over the past 6 years, most recently at -$0.26 for Q1 2026.
- Quarterly results put EPS (Weighted Average and Diluted) at -$0.26 for Q1 2026, up 3.7% from a year ago — trailing twelve months through Mar 2026 was -$1.31 (down 15.93% YoY), and the annual figure for FY2025 was -$1.32, down 18.92%.
- EPS (Weighted Average and Diluted) reached -$0.26 in Q1 2026 per NVCT's latest filing, up from -$0.31 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at -$0.24 in Q3 2024 and bottomed at -$0.48 in Q4 2022.
- Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.31 (2025), compared with a mean of -$0.33.
- Peak annual rise in EPS (Weighted Average and Diluted) hit 80.42% in 2022, while the deepest fall reached 3300.0% in 2022.
- Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.48 in 2022, then increased by 14.58% to -$0.41 in 2023, then rose by 12.2% to -$0.36 in 2024, then rose by 13.89% to -$0.31 in 2025, then grew by 16.13% to -$0.26 in 2026.
- Business Quant data shows EPS (Weighted Average and Diluted) for NVCT at -$0.26 in Q1 2026, -$0.31 in Q4 2025, and -$0.44 in Q3 2025.